Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLQ | O75417 | 20/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31418645 | 0.92 | POLQ (0.56) | POLQ | |
| SCHEMBL25309490 | 0.92 | POLQ (0.56) | POLQ | |
| SCHEMBL31119733 | 0.86 | POLQ (0.47) | POLQ | |
| SCHEMBL24500339 | 0.84 | POLQ (0.61) | POLQ | |
| SCHEMBL24501510 | 0.84 | POLQ (0.50) | POLQ | |
| SCHEMBL30640125 | 0.84 | POLQ (0.61) | POLQ | |
| SCHEMBL30640176 | 0.84 | POLQ (0.50) | POLQ | |
| SCHEMBL24769329 | 0.84 | POLQ (0.53) | POLQ | |
| SCHEMBL31541658 | 0.84 | POLQ (0.53) | POLQ | |
| SCHEMBL24770187 | 0.84 | POLQ (0.52) | POLQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4676480-A1 | INHIBITORS OF DNA POLYMERASE THETA | Breakpoint Therapeutics GmbH (DE) | 2026-01-14 | — | — | EP | disclosed |
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-12-10 | — | — | US | disclosed |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-11-19 | — | — | US | disclosed |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-10 | — | — | US | disclosed |
| US-20240327430-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-10-03 | — | — | US | disclosed |
| WO-2024189493-A1 | INHIBITORS OF DNA POLYMERASE THETA | BREAKPOINT THERAPEUTICS GMBH (DE) | 2024-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162895-B2 | DNA polymerase theta inhibitor for treatment of cancer | POLQ, POLB, POLH | POLQ 1/4885 |
| US-20240327430-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | POLQ 1/4885 |
| US-20240336628-A1 | NOVEL COMPOUNDS, COMPOSITIONS, AND THERAPEUTIC USES THEREOF | POLQ, POLK, POLB | POLQ 1/4885 |
| US-20240327431-A1 | DNA POLYMERASE THETA INHIBITOR FOR TREATMENT OF CANCER | POLQ, POLB, POLH | POLQ 1/4885 |
| US-12145945-B2 | Compounds, compositions, and therapeutic uses thereof | POLQ, POLK, POLB | POLQ 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.